{"organizations": [], "uuid": "717eda7fa83cb347e2165bdae8f94e2c927ff417", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/05/02/the-associated-press-exelixis-1q-earnings-snapshot.html", "country": "US", "domain_rank": 767, "title": "Exelixis: 1Q Earnings Snapshot", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T02:09:00.000+03:00", "replies_count": 0, "uuid": "717eda7fa83cb347e2165bdae8f94e2c927ff417"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/05/02/the-associated-press-exelixis-1q-earnings-snapshot.html", "ord_in_thread": 0, "title": "Exelixis: 1Q Earnings Snapshot", "locations": [], "entities": {"persons": [], "locations": [{"name": "san francisco", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}, {"name": "south san francisco", "sentiment": "none"}], "organizations": [{"name": "exelixis inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}, {"name": "exelixis", "sentiment": "none"}, {"name": "exel", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SOUTH SAN FRANCISCO, Calif. (AP) â€” Exelixis Inc. (EXEL) on Wednesday reported first-quarter earnings of $115.9 million.\nThe South San Francisco, California-based company said it had profit of 37 cents per share.\nThe results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 16 cents per share.\nThe drug developer posted revenue of $212.3 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $146.4 million.\nExelixis expects its total costs and operating expenses for the full year will be between $430 million and $460 million.\nExelixis shares have fallen 32 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $20.62, a decrease of 11 percent in the last 12 months.\nElements of this story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on EXEL at https://www.zacks.com/ap/EXEL\nThis story has been corrected to read that the company expects its full-year total costs and operating expenses will be between $430 million and $460 million, not its full-year revenue.", "external_links": ["https://www.zacks.com/ap/EXEL", "http://automatedinsights.com/ap"], "published": "2018-05-03T02:09:00.000+03:00", "crawled": "2018-05-03T09:25:14.000+03:00", "highlightTitle": ""}